NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中央核肌肉病變 (CNM) - 流行病學考察:2030年

Centronuclear Myopathy (CNM) - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966765
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
中央核肌肉病變 (CNM) - 流行病學考察:2030年 Centronuclear Myopathy (CNM) - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供中央核肌肉病變 (CNM) 調查分析,過去、未來的流行病學,以美國、歐洲5個國家 (德國,西班牙,義大利,法國,英國) 、日本的市場趨勢為焦點,提供治療流程、治療指南,流行病學方案相關的系統性資訊。

目錄

第1章 主要考察

第2章 中央核肌肉病變 (CNM)的摘要整理

第3章 中央核肌肉病變 (CNM) :疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷

第4章 病人歷程

第5章 流行病學和患者族群

  • 流行病學的主要調查結果
  • 前提條件與根據:主要7個國家
  • 流行病學方案:主要7個國家
  • 美國的流行病學
  • 歐洲5個國家的各國流行病學
  • 日本的流行病學

第6章 治療流程,目前治療,醫療行為

  • 中央核肌肉病變 (CNM)的治療與管理
  • 中央核肌肉病變 (CNM)的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1040

DelveInsight's 'Centronuclear Myopathy (CNM) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Centronuclear Myopathy (CNM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Centronuclear Myopathy (CNM) Understanding

The DelveInsight Centronuclear Myopathy (CNM) epidemiology report gives a thorough understanding of the Centronuclear Myopathy (CNM) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Centronuclear Myopathy (CNM) in the US, Europe, and Japan. The report covers the detailed information of the Centronuclear Myopathy (CNM) epidemiology scenario in seven major countries (US, EU5, and Japan).

Centronuclear Myopathy (CNM) Epidemiology Perspective by DelveInsight

The Centronuclear Myopathy (CNM) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Centronuclear Myopathy (CNM) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Centronuclear Myopathy (CNM) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Centronuclear Myopathy (CNM) Detailed Epidemiology Segmentation

The Centronuclear Myopathy (CNM) epidemiology covered in the report provides historical as well as forecasted Centronuclear Myopathy (CNM) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Centronuclear Myopathy (CNM) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Centronuclear Myopathy (CNM) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Centronuclear Myopathy (CNM) Epidemiology Report and Model provide an overview of the risk factors and global trends of Centronuclear Myopathy (CNM) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Centronuclear Myopathy (CNM) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Centronuclear Myopathy (CNM)
  • The report provides the segmentation of the Centronuclear Myopathy (CNM) epidemiology

Report Highlights:

  • 11-Year Forecast of Centronuclear Myopathy (CNM) epidemiology
  • 7MM Coverage
  • Total Cases of Centronuclear Myopathy (CNM)
  • Total Cases of Centronuclear Myopathy (CNM) according to segmentation
  • Diagnosed cases of Centronuclear Myopathy (CNM)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Centronuclear Myopathy (CNM) ?
  • What are the key findings pertaining to the Centronuclear Myopathy (CNM) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Centronuclear Myopathy (CNM) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Centronuclear Myopathy (CNM) ?
  • What are the currently available treatments of Centronuclear Myopathy (CNM) ?

Reasons to buy:

  • The Centronuclear Myopathy (CNM) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Centronuclear Myopathy (CNM) market
  • Quantify patient populations in the global Centronuclear Myopathy (CNM) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Centronuclear Myopathy (CNM) therapeutics in each of the markets covered
  • Understand the magnitude of Centronuclear Myopathy (CNM) population by its epidemiology
  • The Centronuclear Myopathy (CNM) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Centronuclear Myopathy (CNM)

3. Centronuclear Myopathy (CNM) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Centronuclear Myopathy (CNM) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Centronuclear Myopathy (CNM) Treatment and Management
  • 6.2. Centronuclear Myopathy (CNM) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Centronuclear Myopathy (CNM) Epidemiology in 7MM (2017-2030)
  • Table 2: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Centronuclear Myopathy (CNM) Epidemiology in the United States (2017-2030)
  • Table 4: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Centronuclear Myopathy (CNM) Epidemiology in Germany (2017-2030)
  • Table 6: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Centronuclear Myopathy (CNM) Epidemiology in France (2017-2030)
  • Table 8: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Centronuclear Myopathy (CNM) Epidemiology in Italy (2017-2030)
  • Table 10: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Centronuclear Myopathy (CNM) Epidemiology in Spain (2017-2030)
  • Table 12: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Centronuclear Myopathy (CNM) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Centronuclear Myopathy (CNM) Epidemiology in Japan (2017-2030)
  • Table 16: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Centronuclear Myopathy (CNM) Epidemiology in 7MM (2017-2030)
  • Figure 2: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Centronuclear Myopathy (CNM) Epidemiology in the United States (2017-2030)
  • Figure 4: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Centronuclear Myopathy (CNM) Epidemiology in Germany (2017-2030)
  • Figure 6: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Centronuclear Myopathy (CNM) Epidemiology in France (2017-2030)
  • Figure 8: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Centronuclear Myopathy (CNM) Epidemiology in Italy (2017-2030)
  • Figure 10: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Centronuclear Myopathy (CNM) Epidemiology in Spain (2017-2030)
  • Figure 12: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Centronuclear Myopathy (CNM) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Centronuclear Myopathy (CNM) Epidemiology in Japan (2017-2030)
  • Figure 16: Centronuclear Myopathy (CNM) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report